Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic Analysis AS's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €-0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.01.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 45.00% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 27.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Genetic Analysis AS's EPS without NRI or its related term are showing as below:
FRA:8V8'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.9 Med: 15.05 Max: 45
Current: 45
During the past 7 years, Genetic Analysis AS's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 45.00% per year. The lowest was -59.90% per year. And the median was 15.05% per year.
FRA:8V8's 3-Year EPS without NRI Growth Rate is ranked better than 80.5% of 159
companies
in the Medical Diagnostics & Research industry
Industry Median: 10.8
vs FRA:8V8: 45.00
Genetic Analysis AS's EPS (Basic) for the
three
months ended in Mar. 2026 was €-0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.01.
Genetic Analysis AS (FRA:8V8) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Genetic Analysis AS EPS without NRI Related Terms
Genetic Analysis AS EPS without NRI Historical Data
* Premium members only.
The historical data trend for Genetic Analysis AS's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8V8 vs TMO, DHR, IDXX: EPS without NRI Comparison
For the Diagnostics & Research subindustry, Genetic Analysis AS's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS PE Ratio without NRI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Analysis AS (FRA:8V8) has a EPS without NRI of €-0.01 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Genetic Analysis AS and its competitors. According to the industry distribution chart, Genetic Analysis AS ranks #31 out of 159 companies in the Medical Diagnostics & Research industry, placing it in the top 19.5%.
Is Genetic Analysis AS's EPS without NRI too high?
Genetic Analysis AS's current EPS without NRI is €-0.01. Based on the distribution chart, Genetic Analysis AS ranks #31 out of 159 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Genetic Analysis AS has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's EPS without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #31 out of 159 companies for EPS without NRI. This places Genetic Analysis AS in the top 20% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 10.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.80, based on 159 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Genetic Analysis AS and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Analysis AS's current EPS without NRI is €-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Genetic Analysis AS (FRA:8V8) has a current EPS without NRI of €-0.01. The stock's GF Value™ is €0.04, compared to a current price of €0.04 — trading 6.5% above its estimated fair value. The current EPS without NRI is €-0.01. Genetic Analysis AS's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Genetic Analysis AS (FRA:8V8), the current EPS without NRI is €-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (FRA:8V8) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of €0.04 is trading 6.5% above its estimated GF Value™ of €0.04.
Key valuation signals for FRA:8V8:
EPS without NRI: €-0.01
GF Value™: €0.04 vs. price of €0.04 (6.5% above fair value)
No single metric tells the full story. See the FRA:8V8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
39GF Score
Get the complete analysis for FRA:8V8
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8V8 has been successfully added to your 
